General Information of Drug (ID: DMUJCBT)

Drug Name
Altiratinib Drug Info
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
PubChem CID
54576299
CAS Number
CAS 1345847-93-9
TTD Drug ID
DMUJCBT

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Entrectinib DMMPTLH Non-small-cell lung cancer 2C25 Approved [4]
Repotrectinib DM9FB2T Non-small-cell lung cancer 2C25 Approved [5]
Larotrectinib DM26CQR Solid tumour/cancer 2A00-2F9Z Approved [6]
MIM-D3 DMZHN5B Alzheimer disease 8A20 Phase 3 [7]
SNA-120 DMPN314 Plaque psoriasis EA90.0 Phase 2 [8]
CT 327 DMQXL1T Plaque psoriasis EA90.0 Phase 2 [9]
ONO-7579 DMXLPYE Solid tumour/cancer 2A00-2F9Z Phase 1/2 [5]
PLX7486 DM0IVGU Pancreatic cancer 2C10 Phase 1 [10]
DS-6051 DM0RD4F Solid tumour/cancer 2A00-2F9Z Phase 1 [11]
LOXO-195 DMDXFBJ Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Proto-oncogene c-Met (MET)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Crizotinib DM4F29C Non-small-cell lung cancer 2C25.Y Approved [12]
Cabozantinib DMIYDT4 Medullary thyroid gland carcinoma Approved [13]
Amivantamab DMZ7AMY Non-small-cell lung cancer 2C25 Approved [14]
Capmatinib DMYCXKL Non-small-cell lung cancer 2C25.Y Approved [15]
Tepotinib DMUQ0E8 Non-small-cell lung cancer 2C25 Approved [16]
RG3638 DMTQJE0 Gastric adenocarcinoma 2B72 Phase 3 [17]
Savolitinib DMALFKX Renal cell carcinoma 2C90 Phase 3 [5]
Beperminogene perplasmid DM6RWBN Critical limb ischemia BD4Y Phase 3 [18]
Tivantinib DMNVP8Q Hepatocellular carcinoma 2C12.02 Phase 3 [19]
MGCD516 DM752PU Solid tumour/cancer 2A00-2F9Z Phase 2/3 [17]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Entrectinib DMMPTLH Non-small-cell lung cancer 2C25 Approved [4]
Larotrectinib DM26CQR Solid tumour/cancer 2A00-2F9Z Approved [6]
MK-2461 DM21WBH Alzheimer disease 8A20 Phase 1/2 [20]
PMID28270021-Compound-WO2016054807Example1 DMD5QEL Chronic pain MG30 Patented [21]
PMID28270010-Compound-Figure24-b DM0QHLK N. A. N. A. Patented [3]
Pyrrolo[2,3-d]pyrimidine derivative 4 DME0WSR Chronic pain MG30 Patented [21]
3-amino-5-benzyl-substituted indazole derivative 1 DMFDURZ Chronic pain MG30 Patented [21]
PMID28270010-Compound-Figure5-1 DM2YAPJ N. A. N. A. Patented [3]
PMID28270021-Compound-WO2015042088Example4 DM6KXOQ Chronic pain MG30 Patented [21]
PMID28270010-Compound-Figure5-2 DMK3GRZ N. A. N. A. Patented [3]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [22]
Romiplostim DM3U7SZ Thrombocytopenia 3B64 Approved [23]
Regorafenib DMHSY1I Gastrointestinal stromal tumour 2B5B Approved [12]
Sunitinib DMCBJSR Acute undifferentiated leukemia Approved [24]
Axitinib DMGVH6N Renal cell carcinoma 2C90 Approved [25]
Vandetanib DMRICNP Solid tumour/cancer 2A00-2F9Z Approved [26]
Pazopanib HCl DM6U9CQ Renal cell carcinoma 2C90 Approved [27]
Fruquintinib DMHOSCQ Colorectal cancer 2B91.Z Approved [28]
Cabozantinib DMIYDT4 Medullary thyroid gland carcinoma Approved [13]
Tivozanib DMUKC5L Renal cell carcinoma 2C90 Approved [29]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AKB-9778 DMKNRYH Diabetic macular edema 9B71.02 Phase 2 [30]
DCC-2036 DMJKFNU Chronic myeloid leukaemia 2A20 Phase 1/2 [5]
CEP-11981 DMYDTJ6 Solid tumour/cancer 2A00-2F9Z Phase 1 [31]
ARRY-614 DMXD93K Arthritis FA20 Discontinued in Phase 1 [32]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione DMDO175 Discovery agent N.A. Investigative [33]
3,4-diphenyl-1H-pyrrole-2,5-dione DMPK6YT Discovery agent N.A. Investigative [33]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione DMGC7RY Discovery agent N.A. Investigative [33]
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione DM3EV9N Discovery agent N.A. Investigative [33]
PMID21561767C8h DMABZH6 Discovery agent N.A. Investigative [34]
(4-Phenoxy-phenyl)-quinazolin-4-yl-amine DMFO8DR Discovery agent N.A. Investigative [35]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Angiopoietin 1 receptor (TEK) TT9VGXW TIE2_HUMAN Inhibitor [2]
NT-3 growth factor receptor (TrkC) TTXABCW NTRK3_HUMAN Inhibitor [3]
Proto-oncogene c-Met (MET) TTNDSF4 MET_HUMAN Inhibitor [2]
Tropomyosin-related kinase A (TrkA) TTTDVOJ NTRK1_HUMAN Inhibitor [3]
Vascular endothelial growth factor receptor 2 (KDR) TTUTJGQ VGFR2_HUMAN Antagonist [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040094)
2 Clinical pipeline report, company report or official report of Deciphera Pharmaceuticals.
3 Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
7 Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. Clin Ophthalmol. 2013; 7: 1275-1285.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis. Acta Derm Venereol. 2015 May;95(5):542-8.
10 National Cancer Institute Drug Dictionary (drug id 747694).
11 National Cancer Institute Drug Dictionary (drug id 766123).
12 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
13 Clinical pipeline report, company report or official report of Exelixis (2011).
14 Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020 Aug;10(8):1194-1209.
15 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
16 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
17 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
18 Beperminogene perplasmid for the treatment of critical limb ischemia. Expert Rev Cardiovasc Ther. 2014 Oct;12(10):1145-56.
19 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7948).
20 MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
21 Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849.
22 Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
23 Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93.
24 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
25 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
26 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
27 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
28 Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635-45.
29 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
30 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
31 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1842).
32 Cmpany report (Arraybiopharma)
33 Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
34 Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3743-8.
35 Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I. Bioorg Med Chem Lett. 2000 Oct 2;10(19):2167-70.